← All trials
NCT00417690
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- Dec 1, 2007
- Completion date
- Oct 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Jacobus PharmaceuticalLead sponsor
- Tel Aviv UniversityOverall official - principal investigator
- Charlotte Gastroenterology & Hepatology, PLLCOverall official - principal investigator
- University of ChicagoOverall official - principal investigator
- Jacobus PharmaceuticalStudy director
- Jacobus PharmaceuticalStudy chair
- Technion UniversityOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.